PharmAla Biotech Holdings, Inc. (MDMA) Stock Statistics & Valuation Metrics

PharmAla Biotech Holdings, Inc. has a market cap or net worth of C$10.57M. The enterprise value is C$9.77M.

PharmAla Biotech Holdings, Inc. has 105,682,710 shares outstanding. The number of shares has decreased by -2.65% in one year.

PharmAla Biotech Holdings, Inc.’s return on equity (ROE) is -0.42 and return on invested capital (ROIC) is -26.27%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, PharmAla Biotech Holdings, Inc. had revenue of 1.04M and earned -823.60K in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -716.82K and capital expenditures -71.89K, giving a free cash flow of -788.70K billion.

PharmAla Biotech Holdings, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

PharmAla Biotech Holdings, Inc. upcoming earnings date is Aug 5, 2025, After Close (Confirmed).

PharmAla Biotech Holdings, Inc. as a current ratio of 1.14, with Debt / Equity ratio of 0.00%

In the past 12 months, PharmAla Biotech Holdings, Inc. has paid -157.43K in taxes.

PharmAla Biotech Holdings, Inc. EV to EBITDA ratio is -12.40, with an EV/FCF ratio of -12.98.

PharmAla Biotech Holdings, Inc. has C$1.51M in cash and marketable securities with C$0.00 in debt, giving a net cash position of -C$1.51M billion.

Gross margin is -163.95%, with operating margin of -62.16%, and net profit margin of -79.55%.

The average price target for PharmAla Biotech Holdings, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―